PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis

PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis

ObjectivePulmonary hypertension (PH) in context with interstitial lung disease (ILD) portends serious clinical consequences and a high rate of mortality. Recently published randomized controlled trials (RCTs) which assessed the pulmonary arterial hypertension (PAH)-specific drugs for pulmonary hyper...

Full description

Bibliographic Details
Main Authors: Ning Zhao, Jun Chen, Mingming Zhang, Lihui Zhou, Lisong Liu, Jie Yuan, Xingxue Pang, Dayi Hu, Xiaoxia Ren, Zhongyi Jin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
pulmonary hypertension
interstitial lung disease
6-min walk distance (6MWD)
treprostinil
pulmonary arterial hypertension (PAH)
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.992879/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.992879/full

Similar Items